
JT Group Launches Ploom AURA and EVO Heated Tobacco Sticks in Japan
TOKYO--(BUSINESS WIRE)-- Japan Tobacco Inc. (JT)(TSE:2914) launches Ploom AURA, its next generation heated tobacco device, on May 27, 2025, in Japan, primarily in its Ploom stores and CLUB JT online shop. In parallel, JT Group will roll out EVO, its exclusive and premium heated tobacco sticks (HTS), to complement Ploom AURA and provide adult consumers with the latest and most technologically advanced propositions in the heated tobacco segment. A nationwide launch of Ploom AURA and EVO will start on July 1 in convenience stores and tobacco retail shops. Ploom AURA will roll out globally in the near future.
The purpose of JT Group's tobacco business is: Creating fulfilling moments. Creating a better future. And with the launch of Ploom AURA in Japan, the world's leading heated tobacco market, JT Group is taking further steps in this direction – bringing to market and adult consumers an innovative and state-of-the-art heated tobacco device, following extensive consumer insights as well as strong research and development.
'In the Reduced-Risk Products (RRP)* category, we are focusing on providing adult consumers with quality products, rooted in technology, consumer insights, and experience and I truly believe Ploom AURA embraces all these aspects and more. The JT Group will continue to prioritize investments in the heated tobacco sticks segment which maintains the strongest and most consistent growth in the RRP space. Over the course of 2025-2027, we are investing 650 billion yen in RRP, and a significant part of this will be towards Ploom AURA, notably on the launch in Japan and globally,' said Takehiko Tsutsui, Executive Vice President of Reduced-Risk Products.
Ploom AURA's key focus is on enhancing flavor and the device leverages SMART HEATFLOW heating technology, delivering sensory satisfaction while enabling consumers to enjoy the full essence and richness of tobacco with the absence of combustion and no smell of smoke. The new Heat Select System offers four modes for users to customize their experience in line with their preferences. The device maintains the delicate and organic curves characteristic of Ploom, while evolving into a compact and slim design – combining elegance and practicality.
EVO is JT Group's global heated tobacco sticks brand, designed to seamlessly enhance Ploom's advanced heating technology and reduced-risk potential. EVO sticks are made from high-quality tobacco leaves, expertly cut and blended to provide a true tobacco taste. An example of meticulous attention to detail, EVO guarantees a satisfying experience with every puff.
The combination of the cutting-edge technology of Ploom AURA, along with the high-quality EVO heated tobacco sticks, will ensure consumers consistently experience pleasurable heated tobacco moments.
'The RRP category is reshaping the global tobacco landscape, and I am confident that Ploom AURA and EVO will play key roles in supporting JT Group's ambition of reaching mid-teens share in the HTS segment by 2028,' added Tsutsui.
*Reduced-Risk Products (RRP): Products with the potential to reduce the risks associated with smoking, such as Heated Tobacco Products, E-Vapor (or vapes), and Oral products like nicotine pouches.
Japan Tobacco Inc. (JT) is a global company headquartered in Tokyo, Japan. It is listed on the primary section of the Tokyo Stock Exchange (ticker: 2914.T). JT Group has approximately 53,000 employees and 62 factories worldwide, operating in three business segments: tobacco, pharmaceutical, and processed food. Within the tobacco business, the largest segment, products are sold in over 130 markets and its flagship brands include Winston, Camel, MEVIUS, and LD. The Group is committed to investing in Reduced-Risk Products and markets its heated tobacco products under its Ploom brand.
Consumers, shareholders, employees, and society are the four stakeholder groups (4S) at the heart of all of JT Group's activities. Inspired by its 'Fulfilling Moments, Enriching Life' purpose, the Group aims to ensure sustainable and valuable contributions to its stakeholders over the long term. In addition to our three business segments, this goal is also supported by D-LAB, the JT Group's corporate R&D initiative, set up to search and create added-value business opportunities. For more information, visit https://www.jt.com/.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
38 minutes ago
- Business Wire
Law Offices of Howard G. Smith Encourages Fortrea Holdings Inc. (FTRE) Investors to Inquire About Securities Fraud Class Action
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Fortrea Holdings Inc. ('Fortrea' or the 'Company') (NASDAQ: FTRE) securities between , inclusive (the 'Class Period'). Fortrea investors have until August 1, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN FORTREA HOLDINGS INC. (FTRE), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On September 25, 2024, the investment bank Jefferies downgraded Fortrea from buy to hold, citing perceived weaknesses in the Company's business model as a contract research organization ('CRO') amid pressure on biotechnology funding and that the cost savings Fortrea expects to achieve by existing transition services agreements ('TSAs') are 'not as material as one might think.' On this news, Fortrea's stock price fell $2.73, or 12.3%, to close at $19.48 per share on September 25, 2024, thereby injuring investors. Then, on December 6, 2024, Baird Equity Research stated that '[g]iven our ongoing concerns around the sector, [Fortrea's] choppy history post spin, and lack of clarity on the abrupt communications course change, we cannot recommend an actionable investment (buy or sell)[.]' On this news, Fortrea's stock price fell $1.90, or 8.1%, to close at $21.67 per share on December 6, 2024. Then, on March 3, 2025, before the market opened, Fortrea announced financial results for the fourth quarter and full year 2024, revealing the Company had missed its previously announced guidance for revenue and adjusted EBITDA for the full year 2024. The Company's financial results revealed full year adjusted EBITDA of $202.5 million, well below the Company's previously announced guidance of $220 million to $240 million. The Company also revealed full year revenue of $2.696 billion, which missed previously announced guidance of $2.7 billion to $2.725 billion. The Company further revealed financial guidance for the full year 2025, which projected declines in revenue and adjusted EBITDA, with revenues of $2.450 billion to $2.550 billion and adjusted EBITDA in the range of $170 million to $200 million. Thomas Pike ('Pike'), the Company's then-Chief Executive Officer ('CEO'), explained that 'full-service work for projects from the pre-spin period,' 'have less revenue and less profitability' and 'post-spin work is not coming on fast enough to offset the pre-spin contract economics.' Pike further revealed 'this older versus newer mix issue will continue to negatively impact our financial performance during 2025.' On this news, Fortrea shares fell $3.47, or 25.1%, to close at $10.38 per share on March 3, 2025, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company's 2025 earnings; (2) Fortrea overstated the cost savings it would likely achieve by exiting the TSAs; (3) as a result, the Company's previously announced EBITDA targets for 2025 were inflated; (4) accordingly, the viability of the Company's post-Spin-Off business model, as well as its business and/or financial prospects, were overstated; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Contact Us To Participate or Learn More: If you purchased Fortrea securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


Business Wire
an hour ago
- Business Wire
Informatica Expands Collaboration with Snowflake Partnership, Enabling Trusted AI-Ready Data Through Snowflake Apache Polaris and Cortex AI Integration
SAN FRANCISCO--(BUSINESS WIRE)-- Informatica (NYSE: INFA), a leader in enterprise AI-powered cloud data management, today announced new product innovations at Snowflake Summit, Snowflake's annual user conference, including expansion of its support for Apache Iceberg ™. These updates help joint customers use both companies' Generative AI (GenAI) technologies to build reliable, enterprise-level AI applications. New Informatica Intelligent Data Management Cloud Application Integration Capabilities for Snowflake Cortex AI (now Generally Available globally): New Cortex AI Connectivity: New connectors for Cortex AI, Cortex Search, Cortex Analyst and Cortex Agents Simplified RAG and Agent Use Case Development: Simplify GenAI application creation for data professionals with no-code development and deployment with Snowflake Cortex AI Informatica is enhancing its Open Table Connector (Apache Iceberg) to support Apache Polaris: New Apache Iceberg Open Table Connector for Snowflake with support for Snowflake Apache Polaris (Private Preview): Informatica Cloud Data Integration's no-code/low-code data pipelines can now load data into Snowflake from over 300 sources using the Iceberg table format. All tables are automatically registered in Snowflake Apache Polaris, enabling seamless interoperability across Snowflake and other query engines (Planned release in July 2025). Informatica Master Data Management Extension for Snowflake: Informatica is launching its Master Data Management (MDM) SaaS Extension for the Snowflake AI Data Cloud, allowing customers to consolidate master and transaction data across multiple sources. The seamless integration between Informatica MDM and the Snowflake platform enables customers to easily load their trusted master data assets from Informatica's MDM SaaS including customer, supplier, product, patient, provider and other domains directly into the Snowflake AI Data Cloud. The integration brings together data from disparate domains, so data practitioners can power their analytics and AI use cases. 'Informatica continues to be at the forefront of Generative AI and Apache Iceberg innovation with Snowflake enabling our joint customers to build for the future with a trusted, AI-ready data foundation,' said Rik Tamm-Daniels, Group Vice President of Strategic Ecosystems and Technology at Informatica. 'Today's announcement underscores our relentless commitment to innovating and leading with Snowflake to deliver greater value for customers through deep product roadmap and partnership alignment.' 'Informatica's Intelligent Data Management Cloud and Generative AI blueprint for Cortex AI provide a rich foundation of trusted data and metadata intelligence that has enabled us to accelerate innovation with Cortex Analyst and deliver GenAI experiences for our end users leveraging Snowflake data,' said Moli Thomas, Senior Director of Enterprise Data and Analytics at HMH Education Company. 'Snowflake and Informatica continue to collaborate and innovate across product development and engineering to support enterprise customers,' said Saptarshi Mukherjee, Director of Product, Data Engineering at Snowflake. 'Informatica's expanded capabilities with the Cortex AI platform and private preview of its support for Snowflake Apache Polaris showcase our shared commitment to deliver an enhanced and seamless experience for enterprise customers using Snowflake to power their AI initiatives.' Join us at booth #1509 and breakout session #AI212 at Snowflake Summit 2025 as we build the future of AI and enterprise applications, empowering organizations to harness the capabilities of advanced data management and GenAI applications. About Informatica Informatica (NYSE: INFA), a leader in AI-powered enterprise cloud data management, helps businesses unlock the full value of their data and AI. As data grows in complexity and volume, only Informatica's Intelligent Data Management Cloud™ delivers a complete, end-to-end platform with a suite of industry-leading, integrated solutions to connect, manage and unify data across any cloud, hybrid or multi-cloud environment. Powered by CLAIRE® AI, Informatica's platform integrates natively with all major cloud providers, data warehouses and analytics tools— giving organizations the freedom of choice, avoiding vendor lock-in and delivering better ROI by enabling access governed data, simplify operations and scale with confidence. Trusted by 5,000+ customers in nearly 100 countries—including over 80 of the Fortune 100—Informatica is the backbone of platform-agnostic, cloud data-driven transformation.
Yahoo
an hour ago
- Yahoo
3 Asian Stocks Estimated To Be Trading At Discounts Of Up To 42.3%
As the Asian markets navigate a complex landscape of trade negotiations and economic policies, investors are keenly watching for opportunities amid fluctuating sentiments. In this environment, identifying undervalued stocks can be particularly rewarding, offering potential value when market conditions stabilize. Name Current Price Fair Value (Est) Discount (Est) PixArt Imaging (TPEX:3227) NT$219.50 NT$436.79 49.7% cottaLTD (TSE:3359) ¥432.00 ¥860.83 49.8% Zhuhai CosMX Battery (SHSE:688772) CN¥13.36 CN¥26.46 49.5% Dive (TSE:151A) ¥915.00 ¥1819.08 49.7% TLB (KOSDAQ:A356860) ₩17230.00 ₩34141.01 49.5% ALUX (KOSDAQ:A475580) ₩10450.00 ₩20815.81 49.8% China Kings Resources GroupLtd (SHSE:603505) CN¥21.44 CN¥42.38 49.4% BalnibarbiLtd (TSE:3418) ¥1165.00 ¥2301.36 49.4% ikeGPS Group (NZSE:IKE) NZ$0.97 NZ$1.92 49.6% MicroPort CardioFlow Medtech (SEHK:2160) HK$0.87 HK$1.71 49.2% Click here to see the full list of 306 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Here's a peek at a few of the choices from the screener. Overview: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company focused on the R&D, manufacturing, and commercialization of innovative drugs in oncology and immunology both in China and globally, with a market cap of approximately HK$75.74 billion. Operations: The company's revenue is primarily derived from its pharmaceuticals segment, which generated CN¥1.93 billion. Estimated Discount To Fair Value: 33.3% Sichuan Kelun-Biotech Biopharmaceutical appears undervalued based on cash flows, trading at 33.3% below its estimated fair value of HK$509.89, with a current price of HK$340.2. The company is advancing in oncology with innovative products like sac-TMT and tagitanlimab, showing promising clinical results and expanding indications. Despite past losses, revenue growth is strong at 25.5%, with profitability expected within three years, driven by robust product pipelines and strategic partnerships. The growth report we've compiled suggests that Sichuan Kelun-Biotech Biopharmaceutical's future prospects could be on the up. Click here to discover the nuances of Sichuan Kelun-Biotech Biopharmaceutical with our detailed financial health report. Overview: Shenzhen Kinwong Electronic Co., Ltd. specializes in the research, development, production, and sale of printed circuit boards and electronic materials both in China and internationally, with a market cap of CN¥29.28 billion. Operations: The company generates revenue primarily from its printed circuit board segment, amounting to CN¥13.26 billion. Estimated Discount To Fair Value: 21.8% Shenzhen Kinwong Electronic is undervalued by over 20%, trading at CN¥31.32 against a fair value of CN¥40.06. The company reported Q1 2025 revenue of CNY 3.34 billion, up from CNY 2.74 billion a year ago, with net income rising to CNY 324.82 million. Despite modest return on equity forecasts (13.5%), earnings are expected to grow significantly at 23.7% annually, outpacing the Chinese market's growth rate and indicating strong future potential despite current dividend coverage issues. Our comprehensive growth report raises the possibility that Shenzhen Kinwong Electronic is poised for substantial financial growth. Dive into the specifics of Shenzhen Kinwong Electronic here with our thorough financial health report. Overview: Suzhou Zelgen Biopharmaceuticals Co., Ltd. is a company that focuses on the research, development, and commercialization of innovative pharmaceutical products, with a market cap of CN¥30.51 billion. Operations: The company's revenue is primarily derived from its Pharmaceuticals segment, amounting to CN¥592.35 million. Estimated Discount To Fair Value: 42.3% Suzhou Zelgen Biopharmaceuticals is trading at CN¥115.25, significantly below its estimated fair value of CN¥199.79, suggesting it may be undervalued based on cash flows. The company's earnings are projected to grow 101.52% annually, with revenue expected to rise 45.4% per year, surpassing the broader Chinese market growth rate of 12.4%. Despite a volatile share price recently and low forecasted return on equity (18.3%), its path towards profitability within three years enhances its investment appeal. Our earnings growth report unveils the potential for significant increases in Suzhou Zelgen BiopharmaceuticalsLtd's future results. Unlock comprehensive insights into our analysis of Suzhou Zelgen BiopharmaceuticalsLtd stock in this financial health report. Gain an insight into the universe of 306 Undervalued Asian Stocks Based On Cash Flows by clicking here. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:6990 SHSE:603228 and SHSE:688266. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data